growth
Медицинские препараты Recordati Ilac Стамбул, Турция
ANNUAL REPORT 2013
RECORDATI: VERY GOOD FIRST NINE MONTHS 2011 RESULTS. SALES +5.8%. NET INCOME +5.8%. INTERIM DIVIDEND DI
İş Girişim | Frik İlaç
Untitled
Untitled
İş Girişim | Frik İlaç
RECORDATI: VERY GOOD FIRST HALF 2011 RESULTS. SALES +6.6%. NET INCOME +5.3%
RECORDATI FINALIZES ITS ACQUISITION OF FRIK İLAÇ IN TURKEY
PATIENTS | PEOPLE | PRODUCTS | PERFORMANCE
INTERIM REPORT FIRST NINE MONTHS 2013
Recordati buys Turkey's Frik Ilac for $130 million - PharmaTimes
Untitled
Untitled
NEWS RELEASE
Untitled
Медицинские препараты Recordati Ilac Стамбул, Турция
Recordati S.p.A - About Us > History
Recordati Company Profile: Stock Performance & Earnings | PitchBook
economiaefinanza - Lettera all'investitore » Recordati, l'Ebitda 2011 è atteso al di sopra dei 190 milioni - Versione stampabile
